Skip Nav Destination
Issues
15 January 2014
-
Cover Image
Cover Image
The cover shows a section of a lymph node biopsy from a patient with mantle cell lymphoma. Hematoxylin and eosin staining shows typical monomorphous small-to-medium–sized lymphoid cells with irregular nuclei. For details, see the article by Moros and colleagues on page 393 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
Molecular Pathways
Reviews
Human Cancer Biology
IgG-Switched CLL Has a Distinct Immunogenetic Signature from the Common MD Variant: Ontogenetic Implications
Anna Vardi; Andreas Agathangelidis; Lesley-Ann Sutton; Maria Chatzouli; Lydia Scarfò; Larry Mansouri; Vassiliki Douka; Achilles Anagnostopoulos; Nikos Darzentas; Richard Rosenquist; Paolo Ghia; Chrysoula Belessi; Kostas Stamatopoulos
Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence
Michael D. Allen; Gareth J. Thomas; Sarah Clark; Marwa M. Dawoud; Sabarinath Vallath; Sarah J. Payne; Jennifer J. Gomm; Sally A. Dreger; Sarah Dickinson; Dylan R. Edwards; Caroline J. Pennington; Ivana Sestak; Jack Cuzick; John F. Marshall; Ian R. Hart; J. Louise Jones
The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
Armelle Luscan; Ghjuvan'Ghjacumu Shackleford; Julien Masliah-Planchon; Ingrid Laurendeau; Nicolas Ortonne; Jennifer Varin; François Lallemand; Karen Leroy; Valérie Dumaine; Mikael Hivelin; Didier Borderie; Thomas De Raedt; Laurence Valeyrie-Allanore; Frédérique Larousserie; Benoît Terris; Laurent Lantieri; Michel Vidaud; Dominique Vidaud; Pierre Wolkenstein; Béatrice Parfait; Ivan Bièche; Charbel Massaad; Eric Pasmant
Cancer Therapy: Preclinical
Author Choice
Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
David A. Proia; Chaohua Zhang; Manuel Sequeira; John-Paul Jimenez; Suqin He; Neil Spector; Geoffrey I. Shapiro; Sara Tolaney; Masazumi Nagai; Jaime Acquaviva; Donald L. Smith; Jim Sang; Richard C. Bates; Iman El-Hariry
Imaging, Diagnosis, Prognosis
Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity
Alexander Gröbe; Marco Blessmann; Henning Hanken; Reinhard E. Friedrich; Gerhard Schön; Johannes Wikner; Katharina E. Effenberger; Lan Kluwe; Max Heiland; Klaus Pantel; Sabine Riethdorf
Cancer Therapy: Clinical
Author Choice
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Gail D. Lewis Phillips; Carter T. Fields; Guangmin Li; Donald Dowbenko; Gabriele Schaefer; Kathy Miller; Fabrice Andre; Howard A. Burris, III; Kathy S. Albain; Nadia Harbeck; Veronique Dieras; Diana Crivellari; Liang Fang; Ellie Guardino; Steven R. Olsen; Lisa M. Crocker; Mark X. Sliwkowski
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled; Michal Abraham; Irit Avivi; Jacob M. Rowe; Katia Beider; Hanna Wald; Lena Tiomkin; Lena Ribakovsky; Yossi Riback; Yaron Ramati; Sigal Aviel; Eithan Galun; Howard Laurence Shaw; Orly Eizenberg; Izhar Hardan; Avichai Shimoni; Arnon Nagler
Author Choice
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
Johanna C. Bendell; Michael S. Gordon; Herbert I. Hurwitz; Suzanne F. Jones; David S. Mendelson; Gerard C. Blobe; Neeraj Agarwal; Carolyn H. Condon; Dawn Wilson; Amelia E. Pearsall; Yijun Yang; Ty McClure; Kenneth M. Attie; Matthew L. Sherman; Sunil Sharma
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain; Emily Curran; Neil M. Iyengar; Ernesto Diaz-Flores; Rangesh Kunnavakkam; Leslie Popplewell; Mark H. Kirschbaum; Theodore Karrison; Harry P. Erba; Margaret Green; Xavier Poire; Greg Koval; Kevin Shannon; Poluru L. Reddy; Loren Joseph; Ehab L. Atallah; Philip Dy; Sachdev P. Thomas; Scott E. Smith; L. Austin Doyle; Walter M. Stadler; Richard A. Larson; Wendy Stock; Olatoyosi Odenike
Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Selma Ugurel; Thomas Mentzel; Jochen Utikal; Peter Helmbold; Peter Mohr; Claudia Pföhler; Meinhard Schiller; Axel Hauschild; Rüdiger Hein; Eckhardt Kämpgen; Ivonne Kellner; Martin Leverkus; Jürgen C. Becker; Philip Ströbel; Dirk Schadendorf
Predictive Biomarkers and Personalized Medicine
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat; Giampaolo Bianchini; Marlene Thomas; Anton Belousov; Maggie C.U. Cheang; Astrid Koehler; Patricia Gómez; Vladimir Semiglazov; Wolfgang Eiermann; Sergei Tjulandin; Mikhail Byakhow; Begoña Bermejo; Milvia Zambetti; Federico Vazquez; Luca Gianni; José Baselga
Advertisement
